FindTrial
Sign In

An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients with Rheumatoid Arthritis Treated with Methotrexate

An Open-Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Japanese Patients with Rheumatoid Arthritis Treated with Methotrexate

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080221102
Enrollment
Unknown
Registered
2010-05-19
Start date
2010-05-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

investigational material(s) Generic name etc : LY2127399 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigat

Sponsors

Eli Lilly Japan K.K.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: -Have given written informed consent -Women must not be pregnant, breastfeeding or be at risk to become pregnant during study participation

Exclusion criteria

Exclusion criteria: -Have had any safety event during the study for LY2127399 that patients participated in previous -Have received, during previous study, any drugs prohibited in the study protocol which includes unapproved drugs, live vaccines, or any biologic or non-biologic DMARD except for MTX, hydroxychloroquine, sulfasalazine or bucillamine

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026